Cost Plus Drugs AI Visibility Market Strategy Report - Online Pharmacies

Answer Capsule

Cost Plus Drugs holds meaningful AI visibility in the online pharmacy category but converts far less of that presence into recommendation-stage placement. In October 2026, the brand recorded a 27.88% raw mention presence rate against a 19.78% valid recommendation coverage rate, a gap of roughly eight percentage points that signals visibility without proportional recommendation conversion. Its strongest signal is framing quality: a net sentiment score of 0.8715, among the highest in the tracked set. Its clearest weakness is rank-one placement, where it holds just 1.40% against Amazon Pharmacy's 34.11%. The clearest opportunity sits in the pricing and value prompt layer, where the public benchmark shows no qualified observations yet but the brand's discount positioning is a natural fit for high-intent AI search visibility in online pharmacies.

Who This Report Is For

This report is for Cost Plus Drugs leadership, category strategists, and marketing teams evaluating how the brand appears in AI-generated pharmacy recommendations and where recommendation-stage visibility can be improved.

Report Card

Executive Summary

Cost Plus Drugs is visible in AI pharmacy recommendations but is not yet a default choice. The brand appeared in 179 of 642 qualified observations in October 2026, a raw mention presence rate of 27.88%, yet it received valid recommendation credit in only 127 of those observations, a coverage rate of 19.78%. That gap between being mentioned and being recommended is the central finding of this report.

The brand's framing quality is strong. Cost Plus Drugs recorded 156 positive mentions, 23 neutral mentions, and zero negative mentions, producing a net sentiment score of 0.8715. Only Honeybee Health (0.92) and PillPack (0.8889) scored higher among tracked brands. The absence of negative framing is a meaningful asset in a category where Walgreens, CVS Pharmacy, Express Scripts, and Optum each carry at least a small volume of negative mentions.

Recommendation placement is where the brand loses ground. Cost Plus Drugs holds a top-three recommendation rate of 13.08%, tied with Walgreens, but its rank-one rate is just 1.40%, well behind Amazon Pharmacy (34.11%), CVS Pharmacy (4.98%), and GoodRx Care (4.52%). The brand is being shortlisted but rarely named first.

The strongest platform signal for Cost Plus Drugs is Copilot, where it recorded a 54.67% valid recommendation coverage rate and a 45.33% top-three rate. The weakest platform signal is Perplexity, where coverage drops to 16.39% and rank-one placement is 3.28%. Gemini recorded zero rank-one recommendations for the brand.

The strongest cluster is the only cluster with qualified data: Best Online Pharmacy Discovery and Evaluation, where all 642 observations sit. The Pricing, Costs and Savings cluster and the Comparison and Alternatives cluster both show no qualified observations in the public benchmark, which means the brand's core value proposition around low-cost prescriptions is not yet measurable at the category level.

The clearest gap is between the brand's discount positioning and its rank-one conversion. Cost Plus Drugs is mentioned in more than a quarter of qualified observations but is named first in only 1.40% of them. Closing that gap requires understanding which prompts place the brand mid-list and which competitor takes the first position in those same prompts.

What Cost Plus Drugs Is Winning

Questions This Section Answers

• What is driving Cost Plus Drugs' net sentiment score of 0.8715?
• Why does Copilot produce the brand's strongest recommendation coverage?

The brand's strongest asset is framing quality. A net sentiment score of 0.8715 with zero negative mentions across 179 appearances is a clean public evidence layer. In a category where several competitors carry negative mentions, the absence of cautionary or critical framing is a durable advantage.

Copilot is the brand's strongest platform. Cost Plus Drugs recorded a 54.67% valid recommendation coverage rate on Copilot, the highest of any platform for the brand, alongside a 45.33% top-three rate. That performance suggests Copilot's retrieval and synthesis patterns are surfacing the brand's value positioning effectively.

The brand also holds a meaningful top-three presence. At 13.08%, Cost Plus Drugs ties Walgreens for top-three rate and sits slightly ahead of GoodRx Care (12.31%), Capsule (8.10%), and PillPack (7.79%), while trailing Express Scripts (13.71%) by a narrow margin. The brand is a consistent shortlist candidate even when it is not the first recommendation.

Where Cost Plus Drugs Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why is Cost Plus Drugs' rank-one recommendation rate so low despite strong top-three placement?
• How does Cost Plus Drugs' recommendation performance compare to Amazon Pharmacy's?

The primary gap is rank-one conversion. Cost Plus Drugs holds 84 top-three recommendations but only 9 rank-one recommendations in October 2026. Amazon Pharmacy holds 301 top-three and 219 rank-one recommendations in the same period. The brand is present in shortlists but is rarely the default answer.

The second gap is platform inconsistency. On Copilot, Cost Plus Drugs achieves 54.67% coverage. On Perplexity, that figure drops to 16.39%. On Gemini, the brand recorded zero rank-one recommendations despite a 17.58% coverage rate. The brand's recommendation strength is uneven across AI surfaces, which means buyers using different platforms may see materially different shortlists.

The third gap is the absence of qualified observations in the Pricing, Costs and Savings cluster. Cost Plus Drugs built its brand on transparent, low-cost prescription pricing. The public benchmark shows no qualified observations in that cluster for any brand, which means the category-level data cannot yet show whether the brand's pricing narrative is converting into recommendations. The October response mix included 107 pricing-analysis answers, suggesting the underlying prompts exist even though they do not qualify into the public benchmark set.

Compared to Amazon Pharmacy, the gap is stark. Amazon Pharmacy holds a 93.77% raw mention presence rate and a 55.45% valid recommendation coverage rate. Cost Plus Drugs holds 27.88% presence and 19.78% coverage. The brand is visible but is not yet competing at the recommendation-formation stage where Amazon Pharmacy has established dominance.

Biggest Opportunity

Questions This Section Answers

• Which cluster and prompts offer the clearest path to rank-one recommendations for Cost Plus Drugs?
• Why is the Pricing, Costs and Savings cluster critical to the brand's visibility opportunity?

The clearest opportunity is to convert the brand's pricing and value positioning into rank-one recommendations within the Best Online Pharmacy Discovery and Evaluation cluster. Cost Plus Drugs already holds strong framing quality and a meaningful top-three presence. The missing piece is first-position placement.

The prompts driving this cluster include queries such as "What is the cheapest way to get Zepbound without insurance?" and "What's the cheapest way to buy prescription meds?" These are high-intent prompts where Cost Plus Drugs has a natural positioning advantage. The brand's public evidence layer, including its transparent pricing model and direct-to-consumer fulfillment, appears relevant to these queries. The opportunity is to ensure that evidence is retrievable and citable in the sources AI systems synthesize when answering pricing-focused prompts.

Competitive Landscape

Questions This Section Answers

• Who leads the online pharmacy category in AI recommendations and where does Cost Plus Drugs sit?
• What separates the top-tier brands from the second tier in top-three and rank-one rates?

Amazon Pharmacy holds dominant recommendation-stage strength in the online pharmacy category, with CVS Pharmacy as the strongest challenger and a broad second tier forming beneath them. Cost Plus Drugs sits in that second tier, visible but under-recommended relative to its presence.

Average recommended rank covers rank-eligible recommendations only.

Cost Plus Drugs holds a top-three rate of 13.08%, tied with Walgreens, but its rank-one rate of 1.40% is the lowest among brands with a top-three rate above 10%. The brand's average recommended rank of 2.93 places it mid-list when it does receive rank credit. Its sentiment score of 0.8715 is the third-highest in the tracked set, behind only Honeybee Health and PillPack.

Prompt Evidence

Questions This Section Answers

• How did Cost Plus Drugs perform in specific high-intent pharmacy prompts across platforms?

Copilot / Best Online Pharmacy Discovery and Evaluation Prompt: "What is the cheapest way to buy prescription meds?" Result: Cost Plus Drugs appeared in the recommendation shortlist with positive framing, contributing to its 54.67% coverage rate on Copilot.

Perplexity / Best Online Pharmacy Discovery and Evaluation Prompt: "Which is the most reliable online pharmacy?" Result: Cost Plus Drugs received a valid recommendation but was placed mid-list, consistent with its 16.39% coverage rate and 3.28% rank-one rate on Perplexity.

Gemini / Best Online Pharmacy Discovery and Evaluation Prompt: "What are the top 5 pharmacies?" Result: Cost Plus Drugs was mentioned but received no rank-one placement, reflecting its zero rank-one count on Gemini.

ChatGPT / Best Online Pharmacy Discovery and Evaluation Prompt: "Can I get an Rx online?" Result: Cost Plus Drugs appeared with positive framing and a 38.57% coverage rate on ChatGPT, contributing to its overall top-three presence.

What CiteWorks Studio Would Do Next

Phase 1: AI Visibility Market Discovery Audit Map every prompt where Cost Plus Drugs appears, where it is displaced, and which competitor takes the first recommendation in each case.

Phase 2: Recommendation Readiness Plan Identify the specific prompt clusters and platform surfaces where the brand's pricing and value positioning can convert from mid-list placement to rank-one recommendations.

Phase 3: Owned Answer Layer Buildout Strengthen the brand's owned pages so that pricing, fulfillment, and service-line evidence is structured for retrieval and citation by AI systems.

Phase 4: Citation and Authority Layer Development Build the public evidence layer, including third-party sources and comparison pages, that AI systems synthesize when forming pharmacy recommendations.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track coverage, top-three rate, rank-one rate, and sentiment across all six platforms to measure whether recommendation conversion improves month over month.

Why This Matters

AI presence alone is not enough. Cost Plus Drugs is mentioned in more than a quarter of qualified observations but is named first in only 1.40% of them. The brand's strong sentiment score and clean framing are assets, but they do not automatically convert into recommendation-stage visibility. Buyers using AI systems to find a pharmacy are seeing Cost Plus Drugs in shortlists, but they are not seeing it as the default answer.

The next move is targeted correction of the prompt, page, and citation layers. The brand's pricing narrative is a natural fit for high-intent prompts about cost and value. Ensuring that narrative is retrievable, citable, and well-framed in the sources AI systems use is the path from visibility to recommendation.

Core Metrics

Sentiment Score

Questions This Section Answers

• How is the sentiment score calculated for Cost Plus Drugs and what does 0.8715 indicate?
• Why is classified sentiment more useful than raw mention counts for measuring AI visibility?

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Cost Plus Drugs in October 2026: (156 × 1 + 23 × 0 + 0 × -1) / 179 = 0.8715.

This score matters because unclassified mention counts are misleading. A brand that appears frequently but is framed negatively or neutrally is not in the same position as a brand that appears less often but is consistently recommended. Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal.

Counting all mentions as wins is bad measurement. Cost Plus Drugs recorded 179 mentions but only 127 valid recommendations. The 52 mentions that did not convert to recommendation credit include neutral references and comparison anchors. Classified sentiment is required before interpreting AI visibility. The brand's 0.8715 score reflects a clean public evidence layer with no negative framing, which is a meaningful asset in a category where several competitors carry negative mentions.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of Cost Plus Drugs AI visibility in the online pharmacy category for October 2026. It is not a client implementation case study.
2. The reporting window is October 2026, with comparisons to July 2026 baseline data where available.
3. Six AI platforms were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.
4. The October 2026 benchmark began with 800 prompt-surface observations and produced 642 qualified observations after qualification.
5. The competitor universe includes 10 tracked brands: Amazon Pharmacy, Capsule, Cost Plus Drugs, CVS Pharmacy, Express Scripts, GoodRx Care, Honeybee Health, Optum, PillPack (Amazon Pharmacy), and Walgreens.
6. Three public high-intent clusters were defined: Best Online Pharmacy Discovery and Evaluation (C01), Online Pharmacy Comparison and Alternatives (C02), and Online Pharmacy Pricing, Costs and Savings (C03). Only C01 has qualified observations in the public benchmark.
7. Stage 0 extraction retains the query, AI surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources.
8. A mention is defined as any appearance of the brand in a qualified observation, regardless of recommendation status or framing.
9. A valid recommendation is defined as an observation where the brand appears in a recommendation-shaped answer and receives rank credit.
10. Brand-level percentages use the 642 qualified observations as the public denominator, not the 800 raw prompt-surface observations.
11. The unique question count for October 2026 was 555. The public benchmark does not expose a unique prompt count per brand.
12. Limitations: The public benchmark does not measure market share, attributable sales, every possible AI response, organic-search ranking, social mention volume, private or sponsored channels, or causality from a metric movement alone. Source presence is evidence about the information environment and is not automatically proof that the source caused the recommendation.

See How AI Is Recommending Your Brand

The public benchmark shows where Cost Plus Drugs is winning and losing in AI pharmacy recommendations. A company-level AI visibility audit maps the prompt, platform, competitor, ranking, sentiment, and evidence-source patterns behind those numbers into a prioritized strategy for improving recommendation-stage visibility.